Thomas Melchardt

Thomas Melchardt is an Associate Professor in the Department of Internal Medicine III at an institution associated with the email domain @salk.at (likely a medical university in Austria). His research focuses on hematology, medical oncology, and immunotherapy, with an emphasis on clonal evolution in cancers, multiple myeloma, and lymphoma. He has led or co-led multiple research projects analyzing circulating cell-free DNA for tumor monitoring and investigating therapeutic strategies such as bispecific antibodies and combination immunotherapies. His work spans clinical trials, real-world studies, and translational research, contributing to understanding treatment outcomes and adverse events in hematologic malignancies.

Research Projects:

• Clonal architecture in pharyngeal cancer (2017)
• Circulating cell-free DNA monitoring in head and neck cancer (2016–2018)
• Early dynamics of cell-free tumor DNA in Diffuse Large B-Cell Lymphoma (2016–2018)

Key Research Themes:

• Immunotherapy and targeted treatments for hematologic cancers
• Molecular monitoring of tumor burden using liquid biopsy techniques
• Clonal evolution in relapsed/refractory malignancies

Recent Publications:

Recent work includes studies on ocular adverse events with belantamab mafodotin in multiple myeloma, combination immunotherapy strategies targeting PD-L1, and outcomes of pirtobrutinib in mantle cell lymphoma. He has also contributed to randomized trials comparing induction therapies in multiple myeloma, emphasizing quality-of-life metrics.

Grants & Awards:

No specific awards mentioned, but his extensive publication record reflects sustained research excellence.

Advisory Role:

No explicit student advisee list provided, but his projects suggest mentorship in clinical and translational research teams.